Artykuły w czasopismach: „Liver Effect of drugs on”

1

Adedoyin, Adedayo, i Robert A. Branch. "The effect of liver disease on drugs". Current Opinion in Critical Care 3, nr 4 (sierpień 1997): 255–61. http://dx.doi.org/10.1097/00075198-199708000-00002.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Hussein, Raghda R. S., Rasha H. Soliman, Ahmed M. Abdelhaleem Ali, Mona H. Tawfeik i Mohamed E. A. Abdelrahim. "Effect of antiepileptic drugs on liver enzymes". Beni-Suef University Journal of Basic and Applied Sciences 2, nr 1 (marzec 2013): 14–19. http://dx.doi.org/10.1016/j.bjbas.2013.09.002.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Soedarsono, Soedarsono, i Agustinus Rizki Wirawan Riadi. "Tuberculosis Drug-Induced Liver Injury". Jurnal Respirasi 6, nr 2 (30.05.2020): 49. http://dx.doi.org/10.20473/jr.v6-i.2.2020.49-54.

Pełny tekst źródła

Streszczenie:

Effective tuberculosis (TB) treatment requires a combination of bactericidal and/or bacteriostatic TB drugs. The combination of these regimens is the standard therapy recommended by World Health Organization (WHO). The standard therapy consists of 5 first-line anti-TB drugs (isoniazid, rifampicin, pyrazinamide, ethambutol, and streptomycin). TB drugs have mild to severe side effects. Side effects that arise not only cause mortality and morbidity but also cause the cessation of treatment with the effect of not achieving cure, even arising drug resistance. Drug-induced liver injury (DILI) is a form of side effect that causes the cessation of TB treatment or regimen changes due to treatment failure, relapse, and drug resistance. DILI increases the problem, covering more than 7% of all side effects. DILI is also one of the concerns in the treatment of TB.

Style APA, Harvard, Vancouver, ISO itp.

4

Gastaldelli, Amalia, Norbert Stefan i Hans-Ulrich Häring. "Liver-targeting drugs and their effect on blood glucose and hepatic lipids". Diabetologia 64, nr 7 (20.04.2021): 1461–79. http://dx.doi.org/10.1007/s00125-021-05442-2.

Pełny tekst źródła

Streszczenie:

AbstractThe global epidemic of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) and the high prevalence among individuals with type 2 diabetes has attracted the attention of clinicians specialising in liver disorders. Many drugs are in the pipeline for the treatment of NAFLD/NASH, and several glucose-lowering drugs are now being tested specifically for the treatment of liver disease. Among these are nuclear hormone receptor agonists (e.g. peroxisome proliferator-activated receptor agonists, farnesoid X receptor agonists and liver X receptor agonists), fibroblast growth factor-19 and -21, single, dual or triple incretins, sodium–glucose cotransporter inhibitors, drugs that modulate lipid or other metabolic pathways (e.g. inhibitors of fatty acid synthase, diacylglycerol acyltransferase-1, acetyl-CoA carboxylase and 11β-hydroxysteroid dehydrogenase type-1) or drugs that target the mitochondrial pyruvate carrier. We have reviewed the metabolic effects of these drugs in relation to improvement of diabetic hyperglycaemia and fatty liver disease, as well as peripheral metabolism and insulin resistance. Graphical abstract

Style APA, Harvard, Vancouver, ISO itp.

5

Chandrasekaran A R, Ravichandran S, Bhavani J, Satheesh Kumar D, Saraladevi V i Irfana Asma S. "Effect of Herbal Capsules on the Hepatic Enzymes in Comparison to its Crude Extract". International Research Journal of Pharmaceutical and Applied Sciences 9, nr 3 (14.08.2020): 22–25. http://dx.doi.org/10.26452/irjpas.v9i3.1254.

Pełny tekst źródła

Streszczenie:

Liver, unlike any organ, is the largest solid organ in the body that helps for the metabolism of the drugs and food materials that contained toxins and other substances are metabolized and detoxified in the liver only. The enzymes are present in the liver are cytochrome P450, and other enzymes like SGOT and SGPT are used as evaluation parameters in the liver diseases. Apart from the food, many drugs cause liver damage by causing cellular damage to the liver. The liver enzymes permanently or temporarily imbalanced with the daily consumption of toxic drugs. If this damage is permanent, then the liver regeneration is not possible, and the body loses its capacity to metabolize the drugs and food. Herb and medicinal plants are used to treat liver disorders and help hepatic regeneration. They are found to be effective and safer compared to synthetic drugs. There are a lot of the chemical leads that were isolated from the herbs that are used to treat liver disorders. These leads were also patented for the formulations that are prepared from the extracts that were achieved from the herbs. In conclusion, the extracts of the plant Leptadenia reticulate and piper were incorporated into the herbal capsules. They were investigated for the activity in comparison to the standard drug and the extracts at the dose of 250mg/kg.

Style APA, Harvard, Vancouver, ISO itp.

6

Kim, Kyung-Soo, i Byung-Wan Lee. "Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease". Clinical and Molecular Hepatology 26, nr 4 (1.10.2020): 430–43. http://dx.doi.org/10.3350/cmh.2020.0137.

Pełny tekst źródła

Streszczenie:

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder and is associated with various metabolic diseases, including type 2 diabetes mellitus. There are no approved drugs for NAFLD, and the only approved treatment option is weight reduction. As insulin resistance plays an important role in the development of NAFLD, many anti-diabetic drugs have been evaluated for the treatment of NAFLD. Improvement of liver enzymes has been demonstrated by many anti-diabetic drugs, but histological assessment still remains insufficient. Pioglitazone could become the first-line therapy for T2DM patients with NAFLD, based on evidence of histological improvement in patients with biopsy-proven nonalcoholic steatohepatitis (NASH). Liraglutide, another promising alternative, is not yet recommended in patients with NAFLD/NASH due to limited evidence. Therefore, well-designed randomized controlled trials should be performed in the near future to demonstrate if and how anti-diabetic drugs can play a role in the treatment of NAFLD.

Style APA, Harvard, Vancouver, ISO itp.

7

Kumar, Vinay, Ankur Sharma, Lalit Machawal, K. Nagarajan i Shadab A. Siddiqui. "Effect of Centella asiatica against anti-tuberculosis drugs-induced hepatotoxicity: Involvement of mitochondria and oxidative stress". Journal of Phytopharmacology 3, nr 5 (25.10.2014): 310–15. http://dx.doi.org/10.31254/phyto.2014.3502.

Pełny tekst źródła

Streszczenie:

The liver is an integral organ in the body and plays a vital role for the metabolism of endogenous and exogenous agents. Drug-induced liver toxicity is one of most common cause of liver injury. It accounts for approximately one-half of the cases of acute liver failure and mimics all forms of acute and chronic liver disease. Hepatotoxicity is associated with the first line antituberculosis drugs such as isoniazid and rifampicin. Therefore, there is need of pharmacological interventions for the treatment of hepatotoxicity. The present study was designed to evaluate the hepatoprotective effect of the Centella asiatica extract on anti-TB drugs-induced hepatotoxicity. Hepatotoxicity was induced by administration of anti-TB drugs (isoniazid and rifampicin). Hepatotoxicity was assessed by significant elevation in oxidative stress, mitochondrial complex alterations and elevated levels of liver marker enzymes. Treatment with Centella asiatica (20, 40 mg/kg p.o.) attenuated the anti-TB drugs induced oxidative stress, mitochondrial complex alterations and elevated levels of liver marker enzymes (viz. SGOT, SGPT, ALP). Histopathological studies also show the promising effect. Therefore, the present study shows the hepatotoprotective effect of Centella asiatica. Therefore, Centella asiatica could be a new pharmacological intervention in the treatment of hepatotoxicity.

Style APA, Harvard, Vancouver, ISO itp.

8

Renovaldi, Dede, i Abdul Khalik Adam. "Potential of Sweet Basil (Ocimum basilicum) as a Hepatoprotector Agent for Liver Injury Related to Drugs". Muhammadiyah Medical Journal 1, nr 2 (16.11.2020): 63. http://dx.doi.org/10.24853/mmj.1.2.63-68.

Pełny tekst źródła

Streszczenie:

The use of drugs is one of the most common causes of liver injury, because the liver is the main organ that metabolizes drugs. Little is currently done if there is a liver injury due to the hepatotoxic side effects of a drug. Herbal plants have active natural compounds that have pharmacological effects so they are widely used as alternative treatments. Sweet basil (Ocimum basilicum) is one of the most cultivated plants in Asia. Studies on the use of Ocimum basilicum in medicine have been carried out, one of which is the hepatoprotector effect. Studies indicate that Ocimum basilicum is rich in high antioxidant content (flavonoids, saponins, tannins, sterols, triterpenes, and rosmaniric acid) capable of providing hepatoprotector effects by helping the regeneration process of hepatocyte cells that are damaged by hepatotoxic agents and significantly decreasing liver damage biomarkers. The purpose of this review is to explain the potential of Ocimum basilicum as a hepatoprotective agent for liver injury associated with drugs. The conclusion of this review is Ocimum basilicum has high potential in its utilization as a hepatoprotector against liver injury mainly related to the consumption of drugs that have hepatotoxic effects.

Style APA, Harvard, Vancouver, ISO itp.

9

Renovaldi, Dede, i Abdul Khalik Adam. "Potential of Sweet Basil (Ocimum basilicum) as a Hepatoprotector Agent for Liver Injury Related to Drugs". Muhammadiyah Medical Journal 1, nr 2 (16.11.2020): 21. http://dx.doi.org/10.24853/mmj.1.2.21-26.

Pełny tekst źródła

Streszczenie:

The use of drugs is one of the most common causes of liver injury, because the liver is the main organ that metabolizes drugs. Little is currently done if there is a liver injury due to the hepatotoxic side effects of a drug. Herbal plants have active natural compounds that have pharmacological effects so they are widely used as alternative treatments. Sweet basil (Ocimum basilicum) is one of the most cultivated plants in Asia. Studies on the use of Ocimum basilicum in medicine have been carried out, one of which is the hepatoprotector effect. Studies indicate that Ocimum basilicum is rich in high antioxidant content (flavonoids, saponins, tannins, sterols, triterpenes, and rosmaniric acid) capable of providing hepatoprotector effects by helping the regeneration process of hepatocyte cells that are damaged by hepatotoxic agents and significantly decreasing liver damage biomarkers. The purpose of this review is to explain the potential of Ocimum basilicum as a hepatoprotective agent for liver injury associated with drugs. The conclusion of this review is Ocimum basilicum has high potential in its utilization as a hepatoprotector against liver injury mainly related to the consumption of drugs that have hepatotoxic effects.

Style APA, Harvard, Vancouver, ISO itp.

10

Werner, Maureen J. M., Jelle Adelmeijer, Vincent E. de Meijer, Ruben H. J. de Kleine, René Scheenstra, Sander T. H. Bontemps, Koen M. E. M. Reyntjens, Jan B. F. Hulscher, Robert J. Porte i Ton Lisman. "In Vitro Evaluation of Pro- and Anticoagulant Drugs in Children with End-Stage Liver Disease Undergoing Liver Transplantation". Thrombosis and Haemostasis 120, nr 09 (6.07.2020): 1240–47. http://dx.doi.org/10.1055/s-0040-1713752.

Pełny tekst źródła

Streszczenie:

Abstract Background Pro- and anticoagulant drugs are commonly used in pediatric liver transplantation to prevent and treat thrombotic and bleeding complications. However, the combination of baseline hemostatic changes in children with liver disease and additional changes induced by transplantation makes this very challenging. This study aimed to analyze the efficacy of clinically available pro- and anticoagulant drugs in plasma from children undergoing liver transplantation. Methods In vitro effects of pro- and anticoagulant drugs on thrombin generation capacity were tested in plasma samples of 20 children (≤ 16 years) with end-stage liver disease undergoing liver transplantation, and compared with 30 age-matched healthy controls. Results Addition of pooled normal plasma had no effect in patients or controls, while 4-factor prothrombin complex concentrate increased thrombin generation in both patients and controls, with enhanced activity in patients. At start of transplantation, dabigatran and unfractionated heparin had a higher anticoagulant potency in patients, whereas 30 days after transplantation low molecular weight heparin was slightly less effective in patients. Effects of rivaroxaban were comparable between patients and controls. Conclusion This study revealed important differences in efficacy of commonly used pro- and anticoagulant drugs in children with end-stage liver disease undergoing liver transplantation. Therefore, dose adjustments of these drugs may be required. The results of this study may be helpful in the development of urgently needed protocols for strategies to prevent and treat bleeding and thrombotic complications in pediatric liver transplantation.

Style APA, Harvard, Vancouver, ISO itp.

11

Lodewijk, L., A. Mall, C. W. Spearman i D. Kahn. "Effect of Liver Regeneration on the Pharmacokinetics of Immunosuppressive Drugs". Transplantation Proceedings 41, nr 1 (styczeń 2009): 379–81. http://dx.doi.org/10.1016/j.transproceed.2008.10.055.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

Samuel, Didier, i Jean-Charles Duclos-Vallée. "The effect of new HCV drugs on liver transplantation outcomes". Nature Reviews Gastroenterology & Hepatology 12, nr 10 (22.09.2015): 559–60. http://dx.doi.org/10.1038/nrgastro.2015.165.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

Peresada, E. I., P. V. Seliverstov, T. V. Vavilova, V. A. Basharin i V. G. Radchenko. "Safety profile of pharmacotherapy in paitionts with non-alcogolic fatty liver disease". Medical Council, nr 3 (12.05.2019): 69–75. http://dx.doi.org/10.21518/2079-701x-2019-3-69-75.

Pełny tekst źródła

Streszczenie:

NAFLD is a leader among chronic liver diseases worldwide. Polymorbidity of such patients requires the appointment of different groups of drugs. The quality of pharmacological correction, which is determined in achieving the desired therapeutic effect and the absence of adverse reactions of the therapy, depends on the functional state of the liver. In diseases of the liver clearance of drugs is reduced, and the period of their half-life increases. Thus, drugs with high hepatic extraction may increase the risk of overdose. In this connection, prior to therapy, laboratory and instrumental control of liver function is necessary to reduce the risk of its drug damage, side effects of pharmacotherapy and prevention of complications.

Style APA, Harvard, Vancouver, ISO itp.

14

Щекіна, К. Г., G. Belik, D. Semeniv i V. Ulanova. "A comparative study of the hepatotrophic properties of non-steroidal anti-inflammatory drugs". Ukrainian biopharmaceutical journal, nr 1(66) (12.04.2021): 36–41. http://dx.doi.org/10.24959/ubphj.21.303.

Pełny tekst źródła

Streszczenie:

Topicality. Recently, more and more works on the hepatotoxicity of NSAIDs have appeared in the literature. Presumably, all NSAIDs have hepatotoxicity, but the degree of adverse effects on the liver in different drugs is variable. Aim. To study the effect of different generations of NSAIDs on the functional state of the liver of the experimental animals. Materials and methods. Diclofenac sodium, piroxicam, indomethacin, meloxicam and celecocosib were selected for the comparative study. Changes in the functional state of the liver of intact rats during subchronic administration of the drugs selected, as well as their impact on the course of the model hepatitis were determined. The state of the liver was determined by the following indicators: the mass coefficient of the liver, the activity of alanine aminotransferase, alkaline phosphatase, the content of total protein, urea, cholesterol in the blood serum, the level of TBA-active products, diene conjugates, reduced glutathione, catalase and glycogen in the liver homogenate. Results and discussion. It was found that diclofenac, piroxicam, indomethacin in the doses of ED50 by the antiexudative activity when used for 14 days adversely affected the liver of intact animals, as well as worsened the course of the model hepatitis, i.e. had a pronounced hepatotoxic effect. Meloxicam and celecoxib did not show a pronounced adverse effect in the carbon tetrachloride hepatitis, but contributed to the deterioration of the functional state of the liver of intact rats, i.e. had a moderate hepatotoxic effect. Conclusions. By the level of hepatotoxicity the drugs studied can be arranged as follows: diclofenac > indomethacin > piroxicam > meloxicam > celecoxib.

Style APA, Harvard, Vancouver, ISO itp.

15

Liao, Wei, Yan Tang, Zhengcui Hu, Chunyan Wang, Yi Chen, Yi Zhang i Wenhan Fan. "Preparation of Galactosyl Nanoparticles and Their Targeting Efficiency to Hepatocellular Carcinoma". Journal of Nanoscience and Nanotechnology 21, nr 2 (1.02.2021): 987–94. http://dx.doi.org/10.1166/jnn.2021.18666.

Pełny tekst źródła

Streszczenie:

Liver diseases seriously endanger people’s physical health, especially liver cancer, and its morbidity and mortality have increased year by year. The reason why liver cancer is difficult to cure is that in addition to the low lethality of cancer drugs to cancer cells, another important factor is that the drugs do not have liver targeting, and there is no way to efficiently deliver anti-cancer drugs to the liver lesions. Hepatocytes can specifically recognize galactose, therefore the galactosyl liver-targeted drug carrier can deliver the drug to the liver in a targeted manner, so that the drug can be directed to the liver, reduce the dose and times of drug administration, reduce toxic side effects, and reduce the adverse reactions of patients, which is of great significance for the treatment of liver cancer. In this thesis, paclitaxel long-circulating nano-liposomes targeting liver cancer constructed with galactose as raw materials can improve the pharmacokinetics and tissue distribution of traditional formulations of paclitaxel, and enhance the safety and tumor suppressive effect of paclitaxel in vivo.

Style APA, Harvard, Vancouver, ISO itp.

16

Grøndahl, Tor Ø., i Iver A. Langmoen. "Epileptogenic effect of antibiotic drugs". Journal of Neurosurgery 78, nr 6 (czerwiec 1993): 938–43. http://dx.doi.org/10.3171/jns.1993.78.6.0938.

Pełny tekst źródła

Streszczenie:

✓ The epileptogenicity of antibiotic drugs represents a clinical problem, and it is well known that the use of penicillin and certain other preparations can induce seizures. In the present study, the authors investigated the epileptogenic properties of different concentrations of 12 commonly used antibiotic medications belonging to seven separate groups. The drugs were tested in the hippocampus, which has a low threshold for the development of epileptiform activity. The hippocampal slice technique, using rat tissue, was employed since absence of the blood-brain barrier allows administration of the drugs in known concentrations. The preparation was exposed to antibiotics in known concentrations and the amplitude and number of population spikes were recorded. Penicillin G was used as a reference substance. Cloxacillin (≥ 1 gm/liter), cephalothin (≥ 1 gm/liter), gentamicin (≥ 80 mg/liter), chloramphenicol (≥ 1 gm/liter), ciprofloxacin (≥ 50 mg/liter), erythromycin (≥ 1 gm/liter), and ampicillin (≥ 1 gm/liter) showed moderate to marked epileptogenic effects, whereas cefuroxime, clindamycin, cefotaxime, vancomycin, and tobramycin had no epileptogenic effects.

Style APA, Harvard, Vancouver, ISO itp.

17

Vickers, Alison, Anatoly Ulyanov i Robyn Fisher. "Liver Effects of Clinical Drugs Differentiated in Human Liver Slices". International Journal of Molecular Sciences 18, nr 3 (7.03.2017): 574. http://dx.doi.org/10.3390/ijms18030574.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

Ting, Liu, Liu Juan i Yang Jian Qiong. "Effective Components of Hepatoprotective Drugs". Applied Mechanics and Materials 633-634 (wrzesień 2014): 533–36. http://dx.doi.org/10.4028/www.scientific.net/amm.633-634.533.

Pełny tekst źródła

Streszczenie:

Pathological changes in animal models of autoimmune hepatitis and liver cells were similar to the mechanism of injury and viral hepatitis, the thesis of the active component of several common liver substances studied, wild chrysanthemum extract has anti-bacterial, anti-viral, pharmacological effects such as anti-inflammatory and immune liver and nerve protection, Dicliptera polysaccharide with excellent hepatoprotective activity of the liver that can be used as an adjunct to clinical medicine. Introduction

Style APA, Harvard, Vancouver, ISO itp.

19

Kim, Jiwon W., i Paula V. Phongsamran. "Drug-Induced Liver Disease and Drug Use Considerations in Liver Disease". Journal of Pharmacy Practice 22, nr 3 (2.02.2009): 278–89. http://dx.doi.org/10.1177/0897190008328696.

Pełny tekst źródła

Streszczenie:

Chronic liver disease encompasses a large number of hepatic disorders. One of the most important etiologies of liver disease is drug-induced liver disease, which is the leading cause of liver failure in patients referred for liver transplantation in the United States. Drug-induced liver disease can present in all forms of acute and chronic liver disease with highly variable clinical presentations. There is no effective treatment for most drug-induced liver disease and the recognition and prevention of drug-induced liver disease remain the most important management strategy. Drug dosing in patients with liver disease represents an even more challenging task to clinicians, as there is only scant information on biomarkers that can be used to predict the pharmacokinetic changes of drugs in patients with underlying liver disease. Several factors contribute to alterations in drugs metabolism and clearance in cirrhotic patients, including the severity of the liver disease and the metabolic pathways of each individual drug. Only general guidelines on dosage adjustment in patients with hepatic impairment are available. When drugs with extensive hepatic metabolism are required in patients with preexisting liver disease, benefit of therapeutic effect must be evaluated against the risk of toxicity, and the drugs must be initiated with extreme caution with appropriate dosage reduction.

Style APA, Harvard, Vancouver, ISO itp.

20

Torshin, I. Yu, A. M. Lila i O. A. Gromova. "Hepatoprotective effects of chondroitin sulfate and glucosamine sulfate". FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 14, nr 4 (15.01.2022): 537–47. http://dx.doi.org/10.17749/2070-4909/farmakoekonomika.2021.112.

Pełny tekst źródła

Streszczenie:

Background. Long-term use of chondroprotective agents – chondroitin sulfate (CS) and glucosamine sulfate (GS) in the treatment of osteoarthritis puts forward increased requirements for the safety of drugs, primarily in terms of effects on the liver and kidneys.Objective: systematization of data on the effect of chondroprotectors on liver structure and functions.Material and methods. Using the methods of the theory of topological text analysis, an intellectual analysis of 2319 publications on fundamental and clinical studies of the relationship of CS and GS with liver function was carried out. The search was performed by a key query “(chondroitine OR glucosamine) AND (liver OR hepatic OR hepatocy*)” in the PubMed/MEDLINE database.Results. The systematic analysis indicated a pronounced hepatoprotective effect of CS and GS pharmaceutical substances with a high degree of purification from inorganic and organic impurities. By regulating inflammation processes, lymphocyte function, fat and carbohydrate metabolism in the liver, standardized forms of CS and GS have a beneficial effect on fat metabolism, reduce chronic inflammation in the liver, exhibit antitumor and pronounced hepatoprotective effects on various models of liver intoxication.Conclusion. The results of this analysis allow us to assert the high safety of drugs based on pharmaceutical standardized forms of CS and GS in terms of liver function.

Style APA, Harvard, Vancouver, ISO itp.

21

Kouakou Etienne, Effo. "Effect of Alcornea cordifolia Aqueous and Methanolic Leaf Extracts against Antituberculosis Drugs Induced Liver Damage in Rats". International Journal of Pharmaceutics & Pharmacology 5, nr 1 (6.06.2021): 1–11. http://dx.doi.org/10.31531/2581-3080.1000151.

Pełny tekst źródła

Streszczenie:

The hepatoprotective properties of Alchornea cordifolia, a medicinal plant was studied in hepatotoxicity induced animal model with a high dose of paracetamol or carbon tetrachloride. Knowing that antituberculosis drugs also represent a risk factor for hepatotoxicity, could A. cordifolia play a key role to limit their hepatotoxicity? The objective of this study was to assess the histological changes of antituberculosis drugs in rat livers and their evolution after administration of an aqueous and a methanolic leaf extracts of A. cordifolia and therefore estimate their polyphenol and flavonoid contents. Rats were divided into three (3) groups: group 1 was treated with isoniazid; group 2 received the combination of isoniazid and rifampicin and group 3 was given the combination of isoniazid, rifampicin and pyraziamide. For each group of rats, the hepatotoxicant was either administered alone or two hours before administration of an aqueous (200, 400, or 800 mg/kg) or a methanolic (200, 400, or 800 mg/kg) leaf extracts of A. cordifolia each day for 10 days. Animals were sacrificed on day 11 and their livers removed for histolopathological analysis. In addition, total polyphenol and flavonoid contents were estimated in both extracts. Antituberculosis drug combinations caused peliosis lesions, steatosis and hepatocyte necrosis. The liver histology of rats that received extracts after administration of antituberculosis drug combinations showed the ability of extracts to annihilate or alleviate hepatocellular damage caused by such drugs. The methanolic extract, richer in total polyphenols (0.55 ± 0.02 mg EGA) than the aqueous extract (0.35 ± 0.01 mg EGA) demonstrated a greater hepatoprotective effect. Thus, according to liver histological analysis, the aqueous and methanolic leaf extracts of A. cordifolia could attenuate the hepatotoxicity induced by antituberculosis drugs in rats.

Style APA, Harvard, Vancouver, ISO itp.

22

Pereverzev, A. P., O. D. Ostroumova i A. I. Kochetkov. "Drug-induced liver damage with cholestasis". Kachestvennaya klinicheskaya praktika, nr 3 (27.09.2020): 61–74. http://dx.doi.org/10.37489/2588-0519-2020-3-61-74.

Pełny tekst źródła

Streszczenie:

The liver is the main organ responsible for the biotransformation and elimination of drugs, and therefore its function is often impaired by different medications. In this article, the authors inform practical health care professionals about the possible liver damage with cholestasis caused by drugs (DILI). Most often, DILI is caused some antibacterial drugs, steroids, barbiturates and some other drugs. DILI has no pathognomonic clinical manifestations. tte scientific literature describes both an asymptomatic increase of “liver” enzymes and the development of acute liver failure. Important diagnostic methods are the collection of anamnesis (especially the medicinal one), analysis of blood biochemical tests, and data from visual diagnostic methods. If the patient has DILI, it is necessary, whenever possible, to stop intake of a drug. ttere are no specific drugs recommended for pharmacotherapy of DILI but there is some the positive effect of ademetionine and ursodeoxycholic acid. ttere are no specific preventive measures for DILI. Healthcare practitioners are recommended not to use drugs off-label, optimize pharmacotherapy and fight with polypharmacy, monitore biochemical tests regularly etc.

Style APA, Harvard, Vancouver, ISO itp.

23

Gubergrits, N. B., N. V. Byelyayeva, A. Ye Klochkov, G. M. Lukashevich i P. G. Fomenko. "Drug-induced liver injury: from pathogenesis to treatment". Herald of Pancreatic Club 46, nr 1 (26.03.2020): 72–80. http://dx.doi.org/10.33149/vkp.2020.01.10.

Pełny tekst źródła

Streszczenie:

The article presents data on classification, pathogenesis, clinical picture, diagnosis and differentiated treatment tactics, as well as practical algorithm for recognizing and preventing the development of drug-induced liver injury. Pathogenesis of drug-induced liver injury is analyzed, mechanisms of drug metabolism are explained, metabolism phases are described. Four main mechanisms of the pathological effect of drugs on the liver are identified: direct toxic effect on hepatocytes; toxic effect of drug metabolites; immunoallergic liver injury; idiosyncrasy. Peculiar attention is paid to the pathogenesis of drug-induced cholestasis. Direct hepatotoxic reactions develop according to the cytolytic (hepatocellular, parenchymal), cholestatic or mixed option. The most commonly diagnosed clinical variant of drug-induced liver injury is drug-induced hepatitis. Five forms of hepatitis induced by the use of pharmacological agents are distinguished: drug-induced hepatitis with an isolated increase in transaminases (anti-TB drugs, methyldopa, amiodarone, statins); acute hepatitis with jaundice; pseudo-surgical form of acute hepatitis: abdominal pain, fever, jaundice, enlarged gall bladder (cytostatics, antidepressants, antiarrhythmic drugs); severe forms of acute hepatitis with liver failure; chronic drug hepatitis. International diagnostic criteria, basic data on morphological liver changes are presented. Action of ursodeoxycholic acid is explained. It has a litholytic, anticholestatic, cytoprotective, immunomodulating, anti-inflammatory, antitoxic, hypocholesterolemic effect, modulates apoptosis, has a differentiated effect on the regeneration of hepatocytes.

Style APA, Harvard, Vancouver, ISO itp.

24

Pon`kina, Darya, Sergey Kuranov, Mikhail Khvostov, Nataliya Zhukova, Yulia Meshkova, Mariya Marenina, Olga Luzina, Tatyana Tolstikova i Nariman Salakhutdinov. "Hepatoprotective Effect of a New FFAR1 Agonist—N-Alkylated Isobornylamine". Molecules 28, nr 1 (3.01.2023): 396. http://dx.doi.org/10.3390/molecules28010396.

Pełny tekst źródła

Streszczenie:

Free fatty acid receptor-1 (FFAR1) is one of the possible therapeutic targets in the search for new hepatoprotective drugs. FFAR1 agonists were found to have hypolipidemic, antifibrotic, anti-inflammatory, antiproliferative and antioxidant effects in addition to hypoglycemic action. In this work, we conducted a study of the hepatoprotective effect of the compound QS-528 (previously discovered as an agonist of FFAR1) at doses of 60, 90, 120 and 150 mg/kg on carbon tetrachloride (CCl4)-induced liver injury. At the end of the experiment, a biochemical blood assay demonstrated that the introduction of QS-528 dose-dependently reduces the levels of liver enzymes (AST, ALT and ALKP). Histological and morphometric studies of animals’ livers treated with QS-528 at doses of 120 and 150 mg/kg showed a decrease in degenerative/necrotic changes in hepatocytes and an increase in the regenerative activity of the liver. In addition, no toxicity at a single oral dose of 1000 mg/kg and an increase in HepG2 cell viability in vitro were found. Thus, the compound QS-528 was found to exhibit a hepatoprotective effect against CCl4-induced toxic liver damage.

Style APA, Harvard, Vancouver, ISO itp.

25

Xu, Li, Fei Zhang, Chen Xu, Kai-ge Liu, Wei Wu i Ying-xuan Tian. "Is the Prophylactic Use of Hepatoprotectants Necessary in Anti-Tuberculosis Treatment?" Chemotherapy 62, nr 5 (2017): 269–78. http://dx.doi.org/10.1159/000465515.

Pełny tekst źródła

Streszczenie:

Background: Liver injury is one of the serious side effects of anti-tuberculosis (TB) drugs. It is controversial whether hepatoprotectant prophylaxis is efficient and safe in anti-TB treatment, so we aimed to assess the efficacy and safety of hepatoprotectant prophylaxis in patients who had received anti-TB treatment. Methods: PubMed, the Cochrane library, Embase, Ovid, Springer link, Wiley, Elsevier, Web of Science, and the Karger Online Journal were systematically searched prior to April 2016 for articles related to hepatoprotectant prophylaxis in the treatment of TB. A meta-analysis was conducted to estimate the effect of hepatoprotective agents on liver function and adverse events (AEs) in patients who had received anti-TB drugs. The primary outcomes were changes in alanine transaminase (ALT) and aspartate transaminase (AST) levels. The other outcomes were drug-induced liver injury (DILI) and AEs. Results: In our review, 6 trials that involved 1,227 patients were included. Our analysis indicated that hepatoprotective agents exerted protective effects on liver function in patients who had received anti-TB drugs (weighted mean difference, WMD = -7.81, 95% CI [-12.26, -3.37], p = 0.0006 [ALT]; WMD = -7.07, 95% CI [-11.43, -2.72], p = 0.001 [AST]) in any age group. However, in the subgroup analysis of treatment duration, the use of hepatoprotective agents was not associated with significant changes in ALT and AST levels after 2 weeks of treatment and exhibited a positive effect on liver function after 4 weeks of treatment. Moreover, the use of hepatoprotectants significantly decreased the number of DILI cases (risk ratio, RR 0.50, 95% CI [0.34-0.73], p = 0.0004). However, the use of hepatoprotectants led to similar AEs in the control groups (RR 1.07, 95% CI [0.82-1.39], p = 0.62). Conclusions: The use of hepatoprotective drugs may prevent liver injury in patients who are receiving anti-TB drugs without any significant AEs 4 weeks after the initiation of hepatoprotective medication.

Style APA, Harvard, Vancouver, ISO itp.

26

HATANO, MOTOHISA. "Studies on free liver cells of rats. Effect of various drugs." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 18, nr 1 (1987): 87–88. http://dx.doi.org/10.3999/jscpt.18.87.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

27

Bangchang, Kesara Na, Juntra Karbwang i David J. Back. "Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs". Biochemical Pharmacology 44, nr 3 (sierpień 1992): 587–90. http://dx.doi.org/10.1016/0006-2952(92)90453-p.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

Al-Jawad, Faruk H., Zaid Al-Attar i Muayyad S. Abbood. "The Protective Effect of Nitroglycerin, N-Acetyl Cysteine and Metoprolol in CCL4 Induced Animal Model of Acute Liver Injury". Open Access Macedonian Journal of Medical Sciences 7, nr 11 (15.06.2019): 1739–43. http://dx.doi.org/10.3889/oamjms.2019.469.

Pełny tekst źródła

Streszczenie:

OBJECTIVE: The current study was designed to determine the hepatoprotective effect of well-known drugs. Nitroglycerin, N-acetyl cysteine and Metoprolol in acute liver injury induced by CCL4. The antioxidant effects of b-blockers, especially carvedilol, have been described by several investigators. However, for metoprolol, the effect is a bit query as there is only one in-vitro study showing a little hepatoprotective effect. Thus, it is worthy to re-study the hepatoprotective effect of metoprolol. AIM: To explore the possible hepatoprotective effect of Nitroglycerin, N-acetyl cysteine and Metoprolol TartrateMATERIAL AND METHODS: The normal serum values of ALP, AST, ALT, TSB and TSP were determined in 35 healthy rabbits allocated to 5 groups before CCL4 induction and at three occasions 24, 72, 120 hrs after induction by CCL4 and treatment with the tested drugs: Nitroglycerin, N-acetyl cysteine and Metoprolol for five successive days.RESULTS: Showed significant decrease in serum levels of ALP, AST, ALT and TSB with a significant increase in TSP level of all the tested drugs measured at 120 hrs compared with the control and their levels measured at 24, 72 hrs.CONCLUSION: All the tested drugs proved in having a hepatoprotective effect when they are given orally to animals. The histopathological sections of the liver tissue supported the real effect of these drugs in the management of ALI.

Style APA, Harvard, Vancouver, ISO itp.

29

Mohamed, H. T. "Inflammatory stress and idiosyncratic drugs hepatotoxicity in rabbit". Al-Qadisiyah Journal of Veterinary Medicine Sciences 12, nr 2 (30.12.2013): 7. http://dx.doi.org/10.29079/vol12iss2art249.

Pełny tekst źródła

Streszczenie:

Idiosyncratic drug hepatotoxicity is none or time-related, unpredictable, occur infrequently and can be fatal. It was proposed that inflammatory or oxidative stress occurs randomly in patients even after asymptomatic incidence can precipitate drug hepatotoxicity. To measure the hepatotoxicity of diclofenac in rabbit serum following the incidence of inflammatory stress by lipopolysaccharide (LPS) and correlate this to various stress parameters as Malondialdehyde (MDA). 24 rabbits were divided into four groups (6 each) according to the type of treatment. Group 1: control (received normal saline). Group 2 received diclofenac sod. (5mg/kg, orally 3times daily for three days). Group 3: received lipopolysaccharide (150μg/kg, i.v, 24 hours before killing. Group 4: received diclofenac sod. + Lipopolysaccharide (5mg/kg orally + 150μg/kg, i.v 24 hours before killing). Then for each animal were measure, liver M D A, liver enzymes. LPS potentiated the hepatotoxic effect of diclofenac sod. The effect is mediated by oxidative and inflammatory reactions as demonstrated by increase in a liver tissue M D A.

Style APA, Harvard, Vancouver, ISO itp.

30

Bélanger, P. M., i A. Atitsé-Gbeassor. "Effect of nonsteroidal anti-inflammatory drugs on the microsomal monooxygenase system of rat liver". Canadian Journal of Physiology and Pharmacology 63, nr 7 (1.07.1985): 798–803. http://dx.doi.org/10.1139/y85-132.

Pełny tekst źródła

Streszczenie:

The effect of acetylsalicylic acid, ibuprofen, indomethacin, ketoprofen, naproxen, phenylbutazone, and salicylic acid on the microsomal oxidative drug metabolism of rat liver was studied. Pretreatment of the rats with pharmacologic doses of acetylsalicylic acid, indomethacin, and ketoprofen decreased both the demethylase and hydroxylase activities of rat liver microsomes. These effects were paralleled by decreases in microsomal cytochrome P-450 content. The rate of the microsomal reactions was increased after pretreatment with ibuprofen and naproxen but only the former increased the concentration of cytochrome P-450. Phenylbutazone and salicylic acid had no in vivo effect on the hepatic monooxygenase. The addition of 1 mM of ibuprofen, indomethacin, ketoprofen, naproxen, and phenylbutazone to rat liver microsomes inhibit both the aminopyrine N-demethylase and p-nitro-anisole O-demethylase activities. The extent of the inhibition varied between 21 and 73% of the control incubation. Indomethacin, naproxen, and phenylbutazone also decreased the aniline hydroxylase activity to roughly 60% of the control value. Acetylsalicylic acid and salicylic acid had no in vitro effect on the microsomal monooxygenase. The nonsteroidal anti-inflammatory drugs produced a reverse type I binding spectrum with oxidized cytochrome P-450; indomethacin and phenylbutazone were the strongest ligands. There is no correlation between the effect of addition of nonsteroidal anti-inflammatory drugs to the hepatic microsomal homogenate and their in vivo effect on the monooxygenase activity.

Style APA, Harvard, Vancouver, ISO itp.

31

Sukhanov, D. S., E. D. Bazhanova i D. L. Teplyi. "ROLE OF HEPATOPROTECTORS AND IMMUNOMODULATORS IN REGULATION OF HEPATOCYTE APOPTOSIS INDUCED BY ANTITUBERCULOSIS TREATMENT". Annals of the Russian academy of medical sciences 68, nr 8 (19.08.2013): 45–50. http://dx.doi.org/10.15690/vramn.v68i8.723.

Pełny tekst źródła

Streszczenie:

It was currently shown that hepatopathy due to drug toxicity is associated with increased apoptosis of hepatocytes. Therefore, development of drugs which regulate cell death is of great importance. Aim: to involve some hepatoprotectors (ademethionine, reamberin, remaxol) and immunomodulators (cycloferon) into regulation of apoptosis in experimental models of liver first-line antituberculousis drugs (isoniazid, rifampicin, pyrazinamide). Materials and methods: levels of apoptosis (TUNEL), expression of CD95 (receptor of tumor necrosis factor ― by immunohistochemistry), expression of caspase-8, caspase-3 and p53 (Western-blotting) were measured. Results: exposition of first-line antituberculousis drugs leads to dysthrophia of liver parenchyma cells with increased apoptosis of hepatocytes and activation of CD95, caspase-8 (external way) and overexpression of p53 and caspase-3. It was found that reamberin, cycloferon and remaxol have hepatoprotective effect improving liver histology; ademethionine administered by intraperitoneal injection showed no positive effects. Reamberin demonstrated apoptosis-inhibiting effect in the experiment whereas other drugs were found to be apoptosis inductors for hepatocytes in toxic hepatopathy. Conclusions: regulation of apoptosis by cycloferon and remaxol mediated by external and p53-dependent pathway is confirmed by increased expression of CD95 and p53 protein. Ademethionine might induce apoptosis by the intrinsic pathway.

Style APA, Harvard, Vancouver, ISO itp.

32

Joad, A. L. Aumr Thaar, Omar Mohammad Hussein, Ihab Shihab Ahmed, Ali Abdulrahman Rejab, Omer Faiz Hassan i Wael Abdulrazak Abdullah. "Effect of Antiulcer on the Liver functions". Al Mustansiriyah Journal of Pharmaceutical Sciences 17, nr 1 (13.03.2018): 9. http://dx.doi.org/10.32947/ajps.v17i1.64.

Pełny tekst źródła

Streszczenie:

This study was done in Samarra city from 2-8-2015 until 22-12-2015 and 105 sample was collectedand divided to three groups. The first group 35 patientswere take Ranitidine as antiulcer drug and 35 patients were take Omeprazole antiulcer drug and 35 subjects as control. Patientscomparison were done between each group with control get a result if there is any effect on Liver function that the result were decrease in Alanine transferese (ALT), Aspartate transferese (AST), Alkaline phosphatase (ALP) and serum Total Protein (S. Total Protein), and we observed both of Ranitidine and Omeprazole not effect on total serum bilirubin (T.S.B) . The comparison between the two drugs in the impact on function convergent.

Style APA, Harvard, Vancouver, ISO itp.

33

Kalmykova, Z. A., I. V. Kononenko i A. Yu Mayorov. "Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features". Terapevticheskii arkhiv 91, nr 12 (15.12.2019): 115–21. http://dx.doi.org/10.26442/00403660.2019.12.000166.

Pełny tekst źródła

Streszczenie:

Diabetes mellitus (DM) and chronic liver disease (CLD) are pathological conditions associated with each other and reaching epidemic proportions. There is a strong pathogenetic relationship of carbohydrate metabolism disorders and a number of CLD. Common mechanisms that provoke metabolic and autoimmune disorders in the development of various CLD, leading to steatosis, insulin resistance (IR), impaired glucose tolerance and the development of DM are described. Effective glycemic control can have a beneficial effect on the treatment of these patients, and, conversely, there is evidence of a positive effect of CLD therapy on carbohydrate metabolism. This review discusses the correction of carbohydrate metabolism in patients with CLD, the main groups of modern hypoglycemic drugs, mechanisms of their action, the impact on the physiology of the liver, the possibility of using each of these pharmacological groups in patients with impaired liver function. The modern approaches and possibilities of drug effects on the process of fibrogenesis in CLD, the effect of these drugs on carbohydrate metabolism are listed.

Style APA, Harvard, Vancouver, ISO itp.

34

Kogan, A. S., V. V. Lomivorotov, M. N. Deryagin, M. A. Novikov i V. A. Nepomnyashchikh. "HYPOTENSIVE DRUGS EFFECT AND LIVER MONOOXIGENASE FUNCTION IN ARTERIAL HYPERTENSION PATIENTS AFTER ADRENAL HYPERFUNCTION CORRECTION". "Arterial’naya Gipertenziya" ("Arterial Hypertension") 13, nr 4 (28.08.2007): 262–65. http://dx.doi.org/10.18705/1607-419x-2007-13-4-262-265.

Pełny tekst źródła

Streszczenie:

Hypotensive drug tolerance and liver monooxygenase activity were investigated in 24 refractory arterial hypertension patients before and after surgical suppression of adrenal hyperfunction. Liver monooxygenase activity was studied using antipyrine test. It was found that hypotensive drug tolerance was decreased after one and two side operations on adrenal glands. In parallels halftime of antipyrine elimination was shown to be prolonged by 88.5% in 3 months - 3 years after suppression of adrenal hyperfunction. Our findings suggest that the hypotensive drug tolerance diminution may be the consequence of liver monooxygenase activity reduction. This assumption is in accordance with well known the hypotensive drug metabolism by microsomal liver monooxygenases

Style APA, Harvard, Vancouver, ISO itp.

35

Coelho, DR, ACAX De-Oliveira, TEM Parente, BS Leal, LF das Chagas, TN Oliveira, TD Saint’Pierre i FJR Paumgartten. "In vivo and in vitro effects of pentavalent antimony on mouse liver cytochrome P450s". Human & Experimental Toxicology 36, nr 1 (11.07.2016): 33–41. http://dx.doi.org/10.1177/0960327116637110.

Pełny tekst źródła

Streszczenie:

Pentavalent antimonial (Sb5+) drugs such as meglumine antimoniate (MA) are the mainstay treatment of leishmaniases in developing countries. The effects of these compounds on drug-metabolizing enzymes have not been characterized and their potential pharmacokinetic interactions with other drugs are therefore unknown. The present study investigated whether treatment with MA (300 mg Sb5+/kg body weight/day, subcutaneously) for 24 days affected the activities of cytochrome P450 (CYP)1A (ethoxyresorufin- O-deethylase), CYP2A5 (coumarin 7-hydroxylase), CYP2E1 ( p-nitrophenol-hydroxylase), CYP2B9/10 (benzyloxy-resorufin- O-debenzylase), or CYP3A11 (erythromycin- N-demethylase) in the livers of Swiss Webster (SW) and DBA-2 male and female mice. The results showed that CYP2A5-, CYP2E1-, and CYP3A11-catalyzed reactions were unaffected by MA treatment. A decrease in CYP2B9/10 activity was noted in DBA-2 females (but not males) and was not observed in SW males or females. However, repeated MA administration reduced mouse liver CYP1A activity. CYP1A2 messenger RNA (mRNA) levels were not affected by MA and in vitro exposure of mouse liver microsomes to Sb3+ and Sb5+ did not reduce CYP1A activity. These findings suggested that in vivo treatment with Sb5+ drugs depressed CYP1A activity, without downregulating CYP1A2 mRNA expression. Since in vitro treatment of liver microsomes failed to inhibit CYP1A activity, this effect may require intact cells.

Style APA, Harvard, Vancouver, ISO itp.

36

Chu, Shuhan, Hongxu Zhang i Lixin Ding. "Efficiency of Sophora flavescens-Fructus Ligustri Lucidi Drug Pairs in the Treatment of Liver Fibrosis Based on the Response Surface Method". Evidence-Based Complementary and Alternative Medicine 2019 (1.04.2019): 1–9. http://dx.doi.org/10.1155/2019/8609490.

Pełny tekst źródła

Streszczenie:

The pairing of Sophora flavescens and Fructus Ligustri lucidi is taken from Shi Jinmo Medicine. The idea behind this pairing was inspired by the similarity in pharmacological effects of the two herbal drugs, both of which are known to be effective in the treatment and protection against liver fibrosis. To quantitatively study the extent of the interaction between these drugs and the effect of pairing on the treatment of liver fibrosis, an animal model of liver fibrosis mice was established by intraperitoneal injection of low-dose carbon tetrachloride. The drugs were then administered individually, or in predefined compatibility ratio pairs, by gavage, and the effects on indexes of liver fibrosis were observed. The multisynthetic index method was adopted using Matlab software in order to construct a three-dimensional response surface map of the integration effect and conduct interaction analysis of Sophora flavescens and Fructus Ligustri lucidi. The quadratic surface fitting pattern was designed by quadratic regression to determine the optimal range of each drug. The obtained results show that when the compatibility ratio of Sophora flavescens-Fructus Ligustri lucidi drug pairs is less than or equal to 1:1, their therapeutic effect is enhanced by synergy (interaction value ranging between -0.2 and -1). Overall, the synergy of the high-dose drug pairs is stronger than that of the low-dose drug pairs. The optimal dose ranges are 6~12 g and 8~17 g for Sophora flavescens and Fructus Ligustri lucidi, respectively.

Style APA, Harvard, Vancouver, ISO itp.

37

Chalisova, N. I., V. K. Kozlov, A. B. Mulik, E. P. Zatsepin i T. A. Kostrova. "Protective influence of coded amino acids on the development of liver tissue culture in the presence of cytostatic". Toxicological Review, nr 2 (15.05.2020): 48–53. http://dx.doi.org/10.36946/0869-7922-2020-2-47-52.

Pełny tekst źródła

Streszczenie:

An urgent problem is the search for substances that can provide a protective effect in cases of DNA synthesis and repair disorders that arise as a result of side effects of cytostatic drugs used in the treatment of cancer. The aim of this work was to study the effect of 20 encoded amino acids in the presence of Cyclophosphane on the development of organotypic culture of rat liver tissue. The results obtained indicate that Cyclophosphane; which simulates the action of such cytostatic substances; inhibits cell proliferation in the liver tissue. It was also found that the encoded amino acids: asparagine; arginine; and glutamic acid; eliminate the inhibitory effect of Cyclophosphane in liver tissue culture. The growth zone of explants after combined exposure to Cyclophosphane (whose isolated action suppressed the growth zone) and these amino acids increased significantly and reached control values. Thus; the experimental data create the basis for the development of methods for the therapeutic use of the three studied amino acids for the removal of side effects in the treatment with cytostatic drugs.

Style APA, Harvard, Vancouver, ISO itp.

38

Olayonwa, Damilare, i Samuel Oyedeji. "Evaluation of Anti-Retroviral Drugs Effects on Liver Function Tests of HIV Infected Individuals". Journal of Medical and Health Studies 2, nr 2 (3.09.2021): 38–44. http://dx.doi.org/10.32996/jmhs.2021.2.2.4.

Pełny tekst źródła

Streszczenie:

The Human Immunodeficiency Virus (HIV) continues to be a major global public health issue, having claimed more than 35 million lives so far. Antiretroviral therapy, the drug used to treat HIV patients, had been reported to have an adverse effect on patients’ livers. Therefore, this research aims to assess the parameters for measuring liver injury of HIV patients undergoing antiretroviral therapy in Owo and to determine the patients' vulnerability to liver injury. The study sample was divided into five groups comprising Control groups and groups with 6 months, 1 year, 3 years and 5 years’ periods of administration of an antiretroviral drug. Serum was separated from their blood and values of ALT, ALP and BILT were determined. The results of profiling the patients based on values ALT, ALP and BILT indicated that 73%, 71% and 59% of the patients are within the reference range of the parameters, respectively. Further analysis of the percentage of patients likely to have liver diseases indicated that only 3.2% are prone to liver injury. The results of the One-way Analysis of Variance of the mean values of the groups on ALT, ALP and BILT indicated differences in mean values of the groups. It is suggested that a longitudinal study should be carried out to determine the effect of seasonal variation in the value of the studied parameters. It is also suggested that a wider interval of the period for the groups should be used in the future to determine whether there will be a relationship between the period of administration of the drug and the parameters.

Style APA, Harvard, Vancouver, ISO itp.

39

Szweda, Magdalena, Józef Szarek, Zdzisław Kiełbowicz i Beata Szynaka. "Side-Effects of Non-Steroidal Anti-Inflammatory Drugs on the Liver in Dogs and Hepatoprotective Effect of Plant Remedies". Bulletin of the Veterinary Institute in Pulawy 58, nr 3 (1.10.2014): 459–66. http://dx.doi.org/10.2478/bvip-2014-0070.

Pełny tekst źródła

Streszczenie:

Abstract Hepatoprotective effect of plant drugs against hepatic tissue injury induced by non-steroidal anti-inflammatory drugs (NSAIDs) was assessed on Beagle dogs. The adverse effects of carprofen and robenacoxib on the hepatic tissue were evaluated on the basis of histopathological examination of liver sections. It was demonstrated that the use of NSAIDs with liquorice and composed plant remedy Pectosol¯ caused a reduction of hepatic adverse effects induced by the administration of NSAIDs. This fact indicates a hepatoprotective effect of the tested plant remedies during the treatment with NSAIDs. However, the results require further studies on a larger group of animals. Liquorice and Pectosol¯ reduce the hepatic side effects, which develop after the treatment with carprofen and, to a lesser extent, robenacoxib in young Beagles. Such studies allow to investigate the negative and positive effects of using robenacoxib and carprofen in dogs and, therefore, help to limit the NSAID-induced side effects on the liver in these animals.

Style APA, Harvard, Vancouver, ISO itp.

40

Ali, Rasul, Dler Ali, Zhyan Ahmed, Amal Ahmed, Dilvin Hassen i Rozy Tahir. "Comparison of deferasirox and deferoxamine effect on liver enzyme activities and ferritin level in patients with beta-thalassemia". Zanco Journal of Medical Sciences 24, nr 3 (25.12.2020): 354–59. http://dx.doi.org/10.15218/zjms.2020.042.

Pełny tekst źródła

Streszczenie:

Background and objective: Patients on blood transfusion may develop complications related to iron overload and the effects of chelating agents (drugs), which adversely affect the liver in thalassemia, which is a genetic blood disorder of hemoglobin synthesis that causes severe anemia. This study aimed to assess the effect of deferasirox and deferoxamine drugs on liver enzyme activities (aspartate transaminase, alanine transaminase, and alkaline phosphatase), and serum ferritin level in β_thalassemic patients. Methods: This study was carried out in Erbil city from October 2017 to February 2018. Blood specimens were collected in Hawler thalassemia center and Raparin hospital. The samples included 105 individuals; 70 β-thalassemic patients (35 treated by deferasirox as group A and 35 treated by deferoxamine as group B), and 35 healthy individuals (control group C). Results: The serum aspartate transaminase and alkaline phosphatase activities in β-thalassemic patients were higher than that of controls. The serum alanine transaminase activity in the patients' groups showed non-significant elevation than that of controls. The serum ferritin level in the patients was significantly higher than that of controls. Conclusion: Our finding showed that both deferasirox and deferoxamine drugs affect liver enzymes and increase ferritin level. Keywords: β-thalassemia; Deferasirox; Deferoxamine; Liver enzymes; Ferritin.

Style APA, Harvard, Vancouver, ISO itp.

41

Volynets, G. V., i A. I. Khavkin. "Inflammatory bowel disease and drug-induced liver damage". Experimental and Clinical Gastroenterology, nr 10 (23.12.2021): 138–46. http://dx.doi.org/10.31146/1682-8658-ecg-194-10-138-146.

Pełny tekst źródła

Streszczenie:

The article presents the results of a review of publications devoted to the study of the problems of drug-induced liver damage in inflammatory bowel diseases (IBD). The hepatotoxic effect of thiopurines (azathioprine and 6-mercaptopurine) — hepatotoxicity from 0% to 17%; sulfasalazine and mesalamine (hepatotoxicity from 0% to 4%); methotrexate (hepatotoxicity from 15% to 50%); tumor necrosis factor inhibitors (hepatotoxicity up to 75% of cases.), anti-integrins (hepatotoxicity from 2% to 5%); an interleukin 12/23 inhibitor (hepatotoxicity from 0,5% to 2%); Janus-kinase inhibitors is considered (hepatotoxicity from 1% to 2%).Conclusion. The drugs currently used to treat IBD require periodic liver function tests to rule out drug-induced lesions that require therapy correction. As the range of new drugs is rapidly expanding, this requires special observation and discussion in terms of their adverse effects on the liver.

Style APA, Harvard, Vancouver, ISO itp.

42

ÇANKAYA, Murat, i Mehmet KUZUCU. "EFFECT OF SOME DRUGS ON SHEEP LIVER CARBONIC ANHYDRASE I AND II". Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi 8, nr 2 (15.12.2015): 201. http://dx.doi.org/10.18185/eufbed.22429.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Westra, Inge M., Dorenda Oosterhuis, Geny M. M. Groothuis i Peter Olinga. "The Effect of Antifibrotic Drugs in Rat Precision-Cut Fibrotic Liver Slices". PLoS ONE 9, nr 4 (22.04.2014): e95462. http://dx.doi.org/10.1371/journal.pone.0095462.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

Mujgan Sonmez, Fatma, Ercan Demir, Asim Orem, Sermet Yildirmis, Fazil Orhan, Adnan Aslan i Murat Topbas. "Effect of Antiepileptic Drugs on Plasma Lipids, Lipoprotein (a), and Liver Enzymes". Journal of Child Neurology 21, nr 1 (styczeń 2006): 70–74. http://dx.doi.org/10.1177/08830738060210011301.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Wójcikowski, Jacek, Anna Haduch i Władysława Anna Daniel. "Effect of antidepressant drugs on cytochrome P450 2C11 (CYP2C11) in rat liver". Pharmacological Reports 65, nr 5 (wrzesień 2013): 1247–55. http://dx.doi.org/10.1016/s1734-1140(13)71482-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Hann, Seung Kyung, Yoon-Kee Park, Sungbin Im, Sang-Wahn Koo i Ik Byeong Haarn. "The effect on liver transaminases of phototoxic drugs used in systemic photochemotherapy". Journal of the American Academy of Dermatology 26, nr 4 (kwiecień 1992): 646–48. http://dx.doi.org/10.1016/s0190-9622(08)80796-7.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

Kasuya, Fumiyo, Yasushi Miwa, Maya Kazumi, Hiroyuki Inoue i Hiroyuki Ohta. "Effect of Enoxacin, Felbinac, and Sparfloxacin on Fatty Acid Metabolism and Glucose Concentrations in Rat Tissues". International Journal of Toxicology 30, nr 3 (maj 2011): 367–76. http://dx.doi.org/10.1177/1091581810397619.

Pełny tekst źródła

Streszczenie:

Multiple changes in metabolic levels could be useful for understanding physiological toxicity. To explore further risk factors for the convulsions induced by the interaction of nonsteroidal anti-inflammatory and new quinolone antimicrobial drugs, the effect of sparfloxacin, enoxacin, and felbinac on fatty acid metabolism and glucose concentrations in the liver, brain, and blood of rats was investigated. The levels of long-chain acyl-CoAs (C18:1 and C20:4) in the liver and brain were decreased at the onset of convulsions induced by the coadministration of enoxacin with felbinac. Then, glucose concentrations in the liver and blood were decreased, whereas they were increased in a dose-dependant manner in the brain. However, the formation of acyl-CoAs and glucose levels in the liver, brain, and blood was not significantly influenced by enoxacin, felbinac, and sparfloxacin alone, respectively. The disturbance of both fatty acid metabolism and glucose levels might be associated with the increased susceptibility to convulsions, which may contribute to further understanding of the toxic effects associated with these drugs.

Style APA, Harvard, Vancouver, ISO itp.

48

Tokushige, Katsutoshi, Tomomi Kogiso i Hiroto Egawa. "Current Therapy and Liver Transplantation for Portopulmonary Hypertension in Japan". Journal of Clinical Medicine 12, nr 2 (10.01.2023): 562. http://dx.doi.org/10.3390/jcm12020562.

Pełny tekst źródła

Streszczenie:

Portopulmonary hypertension (PoPH) and hepatopulmonary syndrome are severe pulmonary complications associated with liver cirrhosis (LC) and portal hypertension. Three key pathways, involving endothelin, nitric oxide, and prostacyclin, have been identified in the development and progression of pulmonary arterial hypertension (PAH). To obtain a good effect with PAH-specific drugs in PoPH patients, it is important to diagnose PoPH at an early stage and promptly initiate therapy. The majority of therapeutic drugs are contraindicated for Child-Pugh grade C LC, and their effects decrease in the severe PAH stage. Among many LC patients, the measurement of serum brain natriuretic peptide levels might be useful for detecting PoPH. Previously, liver transplantation (LT) for PoPH was contraindicated; however, the indications for LT are changing and now take into account how well the PoPH is controlled by therapeutic drugs. In Japan, new registration criteria for deceased-donor LT have been established for PoPH patients. PoPH patients with a mean pulmonary arterial pressure <35 mmHg and pulmonary vascular resistance <400 dyn/s/cm−5 are indicated for LT, regardless of whether they are using therapeutic drugs. Combined with PAH-specific drugs, LT may lead to excellent long-term outcomes in PoPH patients. We aimed to review current therapies for PoPH, including LT.

Style APA, Harvard, Vancouver, ISO itp.

49

Denic, Kristina, Dino Tarabar, Slobodan Obradovic, Nemanja Stanic, Jelena Spasic i Nenad Ugresic. "Biochemical liver function tests parameters do not indicate any difference in the degree of hepatotoxicity in patients with metastatic colorectal carcinoma treated with conventional anticancer drugs regardless the use of bevacizumab". Vojnosanitetski pregled 74, nr 8 (2017): 757–62. http://dx.doi.org/10.2298/vsp150807221d.

Pełny tekst źródła

Streszczenie:

Background/Aim. Colorectal carcinoma (CRC) is one the most frequent malignant disease with early liver metastasis. It requires the timely use of anticancer drugs. Current treatment of metastatic CRC consists of conventional anticancer drugs use, but they cause liver damage which is manifested by disorder in biochemical liver function parameters. The addition of one of monoclonal antibodies, e.g. bevacizumab improves their therapeutic effect, but its influence on caused biochemical disturbances is not completely known. Therefore the aim of this study was to compare the level of liver function test parameters in patients treated with conventional anticancer drugs with parameters in patients additionally treated with bevacizumab. Methods. The study was performed on the two groups of adult patients with liver metastatic CRC assigned according to the treatment protocol. One group of the patients (n = 44) was treated with FOLFOX4 (the group 1), and the other one (n = 52) with bevacizumab added to FOLFOX4 treatment protocol (the group 2). Depending on the response of patients, the duration of treatment varied from 2 to 6 months. Standard liver function tests were performed before and after the completion of the treatment. Results. Initial values of some biochemical function test parameters [alkaline phosphatase (ALP) in the group 1 of patients, gamma-glutamyl transferase (GGT) and lactate dehydrogenase (LDH) in both groups] were increased in relation to the normal reference values, with some intergroup differences (p = 0.001). Biochemical disturbances of liver function tests in the group of patients treated with conventional anticancer drugs were due to not only their metastases but also due to the hepatotoxic effect of drugs used. After the treatment, significant differences in biochemical liver tests parameters were found in aspartate aminotransferase (AST), alanine aminotransferase (ALP), GGT and LDH, being lower in the group 2 (patients additionally treated by bevacizumab) (p values were: 0.002 for AST; 0.001 for ALP and GGT; 0.000 for LDH). The levels of the other studied parameters, alanine aminotransferase (ALT) bilirubin, and proteins did not differ significantly between groups both pre- or post-treatment. Conclusion. Both, metastatic CRC and treatment with the conventional anticancer drugs induce significant disturbances of several liver function parameters. The addition of bevacizumab to the conventional anticancer drugs did not affect these disturbances.

Style APA, Harvard, Vancouver, ISO itp.

50

Reddy, Prajyoth, Siddharth Srinivasan, Akshay Rao, Rajeev Patil i Pankaj H. Bansode. "Effect of laparoscopy on liver enzymes". International Surgery Journal 7, nr 2 (27.01.2020): 542. http://dx.doi.org/10.18203/2349-2902.isj20200312.

Pełny tekst źródła

Streszczenie:

Background: Laparoscopic procedures have gained popularity in recent days because of advantages like small incision, less postoperative pain and discomfort, short hospital stay, early ambulation and early discharge. Very few studies are available to correlate Laparoscopic Surgeries and liver enzyme elevation. This effect may be due to either CO2 pneumoperitoneum, diathermy extruding liver, injury to branch of the hepatic artery or general anesthesia. This study was done to evaluate the changes in liver enzymes pre-operatively and post-operatively following laparoscopy.Methods: This prospective study included 103 patients who underwent various laparoscopic surgeries over a period of 2 years in Bharati Hospital & Research Centre, Pune, India. Serum AST, ALT and bilirubin levels were measured preoperatively and on post-operative day 1 and post-operative day 3. Patients with coexisting liver disease, Patients on long term use of hepatotoxic drugs, patients who developed complications such as CBD injury, obstruction, infection, leakage and high grade fever during surgery and in the post-operative period were excluded.Results: All laparoscopic procedures cause a transient elevation of serum bilirubin and liver enzymes. Elevation in the liver enzymes correlated directly with the duration of pneumoperitoneum. Elevation in the serum bilirubin but doesn’t correlates with the duration of pneumoperitoneum. These elevations do not have clinical significance in patients with normal hepatic function preoperatively.Conclusions: Duration of laparoscopic procedure should be kept to minimum and undue prolongation should be avoided. Decision to convert the operation to open surgery from a laparoscopic surgery should be prompt.

Style APA, Harvard, Vancouver, ISO itp.

Artykuły w czasopismach na temat „Liver Effect of drugs on”

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych